India · Delayed Price · Currency is INR Akums Drugs and Pharmaceuticals Earnings Call Transcripts
Fiscal Year 2026
-
Q3 FY26 saw robust revenue and EBITDA growth, led by strong CDMO and international branded formulation performance, with margin expansion and improved cash flows. Key projects in Europe and Zambia are progressing, and automation initiatives are underway.
-
Q2 FY 2026 saw a 1.5% revenue decline and a 22% EBITDA drop, mainly due to lower API prices and higher overheads, but strong cash flows and new international contracts support long-term growth. Major expansion in Zambia and Europe is expected to drive future revenue.
-
Revenue and profitability grew in Q1 FY26, led by CDMO and R&D milestones, despite API price declines. Cash position is strong, with a EUR 100 million EU contract advance and robust free cash flow. Mid single-digit growth is targeted for FY26, with European expansion underway.
Fiscal Year 2025
-
FY 2025 saw flat annual revenue amid API price erosion and muted volumes, but Q4 delivered double-digit growth in both revenue and EBITDA. Strong cash flows, a major European contract, and robust international expansion position the company for high single-digit volume growth and margin stability in FY 2026.
-
Secured a EUR 200 million European CDMO contract with commercial supply starting 2027 and received an upfront payment. Q3 EBITDA grew 12% year-over-year despite a 6% revenue decline, with strong CDMO margins and improved free cash flow. API losses narrowed, with break-even targeted in 1–2 years.
-
Q2 FY25 revenue rose 2% sequentially but fell 10% YoY, impacted by lower demand and API price declines. CDMO remains the main revenue driver, while API margins stayed negative. Export expansion and new facilities are expected to support future growth.
-
Q1 FY25 saw 5.1% revenue growth and margin improvement, led by strong CDMO volume gains and operational efficiencies. API price declines impacted revenue realization, but profitability and cash flow improved. Expansion and new facilities are expected to drive future growth.